Novus Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch NVUS and buy or sell other stocks, ETFs, and their options commission-free!About NVUS
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential.
CEODavid-Alexandre C. Gros, MD, MBA
CEODavid-Alexandre C. Gros, MD, MBA
Employees31
Employees31
HeadquartersIrvine, California
HeadquartersIrvine, California
Founded2004
Founded2004
Employees31
Employees31
NVUS Key Statistics
Market cap556.90M
Market cap556.90M
Price-Earnings ratio-1.36
Price-Earnings ratio-1.36
Dividend yield—
Dividend yield—
Average volume1.01M
Average volume1.01M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$4.98
52 Week high$4.98
52 Week low$1.35
52 Week low$1.35
Stock Snapshot
The current Novus Therapeutics(NVUS) stock price is $9.30, with a market capitalization of 556.9M. The stock trades at a price-to-earnings (P/E) ratio of -1.36.
During the trading day, Novus Therapeutics(NVUS) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading activity shows a volume of 0, compared to an average daily volume of 1.01M.
Over the past 52 weeks, Novus Therapeutics(NVUS) stock has traded between a high of $4.98 and a low of $1.35.
Over the past 52 weeks, Novus Therapeutics(NVUS) stock has traded between a high of $4.98 and a low of $1.35.
People also own
Based on the portfolios of people who own NVUS. This list is generated using Robinhood data, and it’s not a recommendation.